Dustin Weidert, OD
Optometrist · Lutcher, LANPI 1083341515
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Glaukos Corporation at 26.7% of the total. 2025 is the largest year on record at $1,156, 8.2 times the $140 reported in 2022.
Across 43 payments — averaging $59.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$686
- Johnson & Johnson Vision Care, Inc.$452
- Bausch & Lomb Americas Inc.$261
- Dompe US, Inc.$242
- Oyster Point Pharma, Inc.$163
- Mallinckrodt Hospital Products Inc.$160
- plus $606 from 7 others
What the payments were for
- Food & beverage$2,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photrexa Viscous and Photrexa$177
- Tecnis IOL$138
- Prokera$134
- AmnioGraft$134
- Acuvue$125
- VEVYE$124
- ACTHAR$117
- Oxervate$117
- INFUSE$117
- BIOTRUE ONE DAY$117
- iDoseTR$110
- TYRVAYA$100
How this compares
$2,571 in reported general payments places this provider in the 70th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 52 | $45,851 |
| Cyclosporine | 14 | $8,799 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $6,030 |
| Prednisolone Acetate | 75 | $3,394 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $1,987 |
| Fluorometholone | 25 | $1,840 |
| Azelastine Hcl | 49 | $1,405 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 99 | $1,318 |
| Latanoprost | 109 | $1,128 |
| Travoprost | 13 | $1,101 |
| MoxifloxacinMoxifloxacin Hcl | 27 | $772 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 11 | $618 |
| ErythromycinErythromycin Base | 44 | $567 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $526 |
| Timolol Maleate | 37 | $205 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Lutcher
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.